Hara Yukiko, Sakurai Kenichi, Enomoto Katsuhisa, Matsumoto Kyoko, Ueda Yuichi, Hagiwara Mio, Waga Eiko, Nagashima Saki, Tani Mayumi, Amano Sadao
Dept. of Surgery, Nihon University School of Medicine, Japan.
Gan To Kagaku Ryoho. 2012 Nov;39(12):2080-2.
We report a case of breast cancer with lymph node metastases. A complete response was recognized in response to nab-paclitaxel as a first-line therapy after recurrence. The patient was a 50-year-old woman who had a tumor in her right breast. We palpated a mass with clear boundaries in her right breast. The tumor was 2 cm in diameter. Core-needle biopsy of the breast tumor led to a diagnosis of invasive ductal carcinoma (estrogen receptor-, progesterone receptor-, and human epidermal growth factor receptor 2-negative). She received 4 cycles of EC (E: 90 mg/m2/tri-weekly; C: 600 mg/m2 /tri-weekly) plus 4 cycles of TC(T: 75 mg/m2/tri-weekly; C: 600 mg/m2/tri-weekly)as preoperative adjuvant chemotherapy. After chemotherapy, she underwent quadrantectomy plus axillary lymph node dissection. Six months after the operation, lymph node metastases were observed in her right supraclavicular lymph nodes. She received 8 cycles of nab-paclitaxel(260 mg/m2/tri-weekly) therapy. After 8 cycles of treatment, ultrasonography and computed tomography revealed the disappearance of the metastatic lymph nodes. Therefore, a clinical complete response was observed.
我们报告一例伴有淋巴结转移的乳腺癌病例。复发后,作为一线治疗,纳布紫杉醇治疗取得了完全缓解。患者为一名50岁女性,右侧乳房有肿瘤。我们在其右侧乳房触诊到一个边界清晰的肿块。肿瘤直径为2厘米。对乳腺肿瘤进行粗针活检后诊断为浸润性导管癌(雌激素受体、孕激素受体和人表皮生长因子受体2均为阴性)。她接受了4个周期的EC方案(E:90mg/m²/每三周一次;C:600mg/m²/每三周一次)加4个周期的TC方案(T:75mg/m²/每三周一次;C:600mg/m²/每三周一次)作为术前辅助化疗。化疗后,她接受了象限切除术加腋窝淋巴结清扫术。术后6个月,在其右侧锁骨上淋巴结观察到淋巴结转移。她接受了8个周期的纳布紫杉醇(260mg/m²/每三周一次)治疗。经过8个周期的治疗后,超声检查和计算机断层扫描显示转移淋巴结消失。因此,观察到临床完全缓解。